McKesson Corporation $MCK Shares Acquired by Hennion & Walsh Asset Management Inc.

Key Points

• Hennion & Walsh Asset Management increased its McKesson stake by 16.9% in the second quarter, bringing its holdings to 11,124 shares valued at approximately $8.4 million. Institutional investors and hedge funds collectively own 85.07% of McKesson.
• McKesson exceeded quarterly expectations with adjusted EPS of $9.93 and revenue of $105.38 billion, up 7.7% year over year. The company set fiscal 2027 EPS guidance at $44.20–$45.00.
• Analysts maintain a generally positive view, with 14 Buy ratings and three Holds producing a “Moderate Buy” consensus and an average price target of $968.93. McKesson also raised its quarterly dividend from $0.82 to $0.94 per share.

Hennion & Walsh Asset Management Inc. grew its position in shares of McKesson Corporation (NYSE:MCK - Free Report) by 16.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,124 shares of the company's stock after purchasing an additional 1,611 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in McKesson were worth $8,405,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. University of Texas Texas AM Investment Management Co. acquired a new position in shares of McKesson in the fourth quarter worth about $25,000. Swiss RE Ltd. purchased a new stake in shares of McKesson during the 4th quarter worth about $26,000. State of Wyoming acquired a new stake in shares of McKesson during the 2nd quarter valued at about $29,000. Kingdom Financial Group LLC. acquired a new stake in shares of McKesson during the 4th quarter valued at about $33,000. Finally, Birchwood Financial Partners Inc. purchased a new position in shares of McKesson in the 4th quarter valued at about $33,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on MCK shares. Citigroup increased their price target on McKesson from $945.00 to $1,000.00 and gave the stock a "buy" rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $875.00 price objective on shares of McKesson in a research report on Friday, May 8th. Weiss Ratings downgraded McKesson from a "buy (b)" rating to a "buy (b-)" rating in a research note on Tuesday, July 7th. Barclays decreased their target price on McKesson from $1,050.00 to $925.00 and set an "overweight" rating on the stock in a research report on Wednesday, June 10th. Finally, JPMorgan Chase & Co. dropped their price target on shares of McKesson from $1,107.00 to $1,015.00 and set an "overweight" rating on the stock in a research note on Friday, May 8th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $968.93.

McKesson Trading Up 0.0%

NYSE:MCK opened at $871.72 on Friday. The stock has a 50 day moving average of $800.68 and a two-hundred day moving average of $840.98. McKesson Corporation has a 12 month low of $637.00 and a 12 month high of $999.00. The firm has a market cap of $101.63 billion, a P/E ratio of 23.33, a price-to-earnings-growth ratio of 1.43 and a beta of 0.30.

McKesson (NYSE:MCK - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, beating the consensus estimate of $9.56 by $0.37. The business had revenue of $105.38 billion for the quarter, compared to the consensus estimate of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The business's quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the business posted $8.26 earnings per share. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, research analysts forecast that McKesson Corporation will post 44.59 earnings per share for the current year.

McKesson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Tuesday, September 1st will be issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Tuesday, September 1st. This is an increase from McKesson's previous quarterly dividend of $0.82. McKesson's payout ratio is 10.06%.

Insider Transactions at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 133 shares of McKesson stock in a transaction on Friday, June 5th. The shares were sold at an average price of $764.00, for a total transaction of $101,612.00. Following the sale, the chief accounting officer owned 632 shares of the company's stock, valued at $482,848. The trade was a 17.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas L. Rodgers sold 2,388 shares of the company's stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $761.09, for a total transaction of $1,817,482.92. Following the sale, the executive vice president directly owned 3,090 shares of the company's stock, valued at $2,351,768.10. The trade was a 43.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 28,748 shares of company stock worth $22,262,035. Company insiders own 0.06% of the company's stock.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Quarterly results exceeded expectations. McKesson reported adjusted earnings of $9.93 per share, ahead of the $9.44-$9.56 analyst consensus range, while revenue rose 7.7% year over year to $105.38 billion, topping estimates. EPS also increased from $8.26 in the prior-year quarter. McKesson Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Specialty pharmaceutical growth drove profitability. Pharma profit rose 19%, supported by specialty medicine demand and oncology growth. Management raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00, broadly in line with or above current analyst expectations. MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise
• Positive Sentiment: Capital returns are becoming more attractive. McKesson plans approximately $5 billion in share repurchases and raised its dividend by 15%, potentially supporting per-share earnings and investor sentiment. McKesson Outlines Fiscal 2027 EPS and Share Repurchases
• Neutral Sentiment: McKesson is rebranding its Medical-Surgical Solutions business as Wellverse ahead of a planned spinoff and potential IPO. The move could unlock value, although it also introduces execution and separation risks. McKesson Debuts Wellverse Name
• Neutral Sentiment: Recent Zacks commentary characterizes MCK as a growth stock, citing earnings growth, specialty-drug exposure and improving fundamentals. However, these articles are analytical opinions rather than new company announcements. McKesson Is an Incredible Growth Stock

McKesson Profile

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source